UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 T2 BIOSYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36571 20-4827488 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 101 Hartwell Avenue, Lexington, Massachusetts 02421 (Address o ...

Achieved record fourth quarter and full-year 2024 sepsis product revenuesLEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 and Recent Commercial Highlights (unaudited) Achieved record product revenues of $2.3 million ...

LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four T2Dx® Instruments to its European (EU) distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market penetration. The multiple instrument sale demonstrates commercial expansion to enable increased utilization of the T2Bacteria® Panel, the T2 ...

LEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has surpassed the shipment of 250,000 sepsis tests, marking a significant milestone that underscores the growing customer adoption of the Company's direct-from-whole-blood technology. A meta-analysis of 14 controlled studies, published in a peer-reviewed medical journal, compared T2 Biosystems' sepsis tests ...

LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2026. The products covered under the contract with Vizient include the T2Dx® Instrument, the T2Bacteria® Panel ...

Exhibit 99.1 T2 Biosystems Business Update October 10, 2024 Trip Taylor, IR Thank you, operator. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Those include statements related to T2 Biosystems' future financial and operating results and plans for developing and marketing new products. Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause ...

T2 Biosystems, Inc. (NASDAQ:TTOO) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Sperzel - Chairman & Chief Executive Officer John Sprague - Chief Financial Officer Conference Call Participants Yi Chen - H.C. Wainwright Operator Greetings. Welcome to the T2 Biosystems Incorporated Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36571 T2 Biosystems, Inc. (Exact name of re ...

LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a ...

T2 Biosystems, Inc. (NASDAQ:TTOO) Business Update Conference Call October 10, 2024 4:30 PM ET Company Participants Trip Taylor - IR John Sperzel - Chairman and CEO Conference Call Participants Eduardo Martinez - H.C. Wainwright Operator Good day, everyone. And welcome to the T2 Biosystems, Inc. Business Update Call. At this time, all participants have been placed in a listen-only mode. And we will open the floor for your questions and comments after the presentation. It is now my pleasure to turn the floor ...